Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B

International Journal of Pharmaceutics

Volumn 354, Issue 1-2, 2008, Pages 235-241

  Khatri, Kapil ^a   Goyal, Amit K ^a   Gupta, Prem N ^a   Mishra, Neeraj ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Chitosan nanoparticles; Hepatitis B; Nasal immunization; pDNA; Vaccine delivery

Indexed keywords

CHITOSAN; CYTOKINE; DEOXYRIBONUCLEASE I; DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; NANOPARTICLE; NUCLEASE; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; COACERVATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GENETIC CODE; GENETIC TRANSFECTION; HEPATITIS B; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; MOUSE; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE CHARGE; SUSTAINED RELEASE PREPARATION; TISSUE LEVEL; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, INTRANASAL; ALUM COMPOUNDS; ANIMALS; CHITOSAN; DEOXYRIBONUCLEASE I; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; IMMUNOGLOBULIN A, SECRETORY; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; NANOPARTICLES; NASAL MUCOSA; PARTICLE SIZE; PLASMIDS; TRANSFECTION; VACCINATION; VACCINES, DNA;

EID: 40849120029     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.11.027     Document Type: Article

References (36)

1. Bivas-Benita M., Laloup M., Versteyhe S., Dewit J., De Braekeleer J., Jongert E., and Borchard G. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. Int. J. Pharm. 266 (2003) 17-27
2. Borchard G. Chitosans for gene delivery. Adv. Drug Deliv. Rev. 52 (2001) 145-150
3. Brooking J., Davis S.S., and Illum L. Transport of nanoparticles across the rat nasal mucosa. J. Drug Target. 9 (2001) 267-279
4. Davis H.L., Michel M.L., and Whalen R.G. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2 (1993) 1847-1851
5. Davis S.S. Nasal Vaccines. Adv. Drug Deliv. Rev. 51 (2001) 21-42
6. Debin A., Kravtzoff R., Santiago J.V., Cazales L., Sperandio S., Melber K., Janowicz Z., Betbeder D., and Moynier M. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 20 (2002) 2752-2763
7. Donnelly J.J., Ulmer J.B., Shiver J.W., and Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15 (1997) 617-648
8. El-Shafy M.A., Kellaway I.W., Taylor G., and Dickinson P.A. Improved nasal bioavailability of FITC-dextran (Mw 4300) from mucoadhesive microspheres in rabbits. J. Drug Target. 7 (2000) 355-361
9. Geissler M., Tokushige K., Chante C.C., Zurawski V.R., and Wands J.R. Cellular and humoral immune responses to hepatitis B virus structural proteins in mice after DNA-based immunization. Gastroenterology 112 (1997) 1307-1320
10. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15 (1998) 1326-1331
11. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., and Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51 (2001) 81-96
12. Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., and Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21 (2003) 1478-1485
13. Isaka M., Yasuda Y., Mizokami M., Kozuka S., Taniguchi T., Matano K., Maeyama J., Mizuno K., Morokuma K., Ohkuma K., Goto N., and Tochikubo K. Mucosal immunization against Hepatitis B virus by intranasal co-administration of recombinant Hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine 19 (2001) 1460-1466
14. Ishii T., Okahata Y., and Sato T. Mechanism of cell transfection with plasmid/chitosan complexes. Biochim. Biophys. Acta 1514 (2001) 51-64
15. Jaganathan K.S., and Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally. Vaccine 24 (2006) 4201-4211
16. Jain S., Singh P., Mishra V., and Vyas S.P. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B. Immunol. Lett. 101 (2005) 41-49
17. Janes K.A., Calvo P., and Alonso M.J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 47 (2001) 83-97
18. Kumar M., Behera A.K., Lockey R.F., Zhang J., Bhullar G., De La Cruz C.P., Chen L.C., Leong K.W., Huang S.K., and Mohapatra S.S. Intranasal gene transfer by chitosan DNA nanospheres protects Balb/c mice against acute respiratory syncytial virus infection. Hum. Gene Ther. 13 (2002) 1415-1425
19. Leclere C., Deriaud E., Rojas M., and Whalen R.G. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell. Immunol. 179 (1997) 97-106
20. Leong K.W., Mao H.-Q., Troung-Le V.L., Roy K., Walsh S.M., and August J.T. DNA-polycation nanospheres as non-viral gene delivery vehicles. J. Control. Release 53 (1998) 183-193
21. Mao H.-Q., Roy K., Troung-Le V.L., Janes K.A., Lin K.Y., Wang Y., August J.T., and Leong K.W. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release 70 (2001) 399-421
22. McNabb P.C., and Tomasi T.B. Host defense mechanisms at mucosal surfaces. Annu. Rev. Microbiol. 35 (1981) 477-496
23. McNeela E.A., O' Connor D., Jabbal-Gill I., Illum L., Davis S.S., Pizza M., Peppoloni S., Rappuoli R., and Mills K.H. A mucosal vaccine against diptheria: formulation of cross reacting material(CRM(197)) of diptheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19 (2000) 1188-1198
24. Nagamoto T., Hattori Y., Takayama K., and Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res. 21 (2004) 671-674
25. Nakane A., Numata A., and Minagawa T. Endogenous tumor necrosis factor, interleukin-6, and gamma interferon levels during Listeria monocytogenes infection in mice. Infect. Immun. 60 (1992) 523-528
26. Partidos C.D. Intranasal vaccines: forthcoming challenges. Pharm. Sci. Technol. Today 3 (2000) 273-280
27. Read R.C., Naylor S.C., Potter C.W., Bond J., Jabbal-Gill I., Fisher A., Illum L., and Jennings R. Effective nasal influenza vaccine delivery using chitosan. Vaccine 23 (2005) 4367-4374
28. Roy K., Mao H.Q., Huang S.K., and Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5 (1999) 387-391
29. Schirmbeck R., Wild J., Stober D., Blum H.E., Chisari F.V., Geissler M., and Reimann J. Ongoing murine T1 or T2 immune responses to the hepatitis B surface antigen are excluded from the liver that expresses transgene encoded hepatitis B surface antigen. J. Immunol. 164 (2000) 4235-4243
30. Seferian P.G., and Martinez M.L. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 19 (2000) 661-668
31. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., Sadovsky R., Morrison J.M., and Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 303 (1980) 833-841
32. van der Lubben I.M., Verhoef J.C., Borchard G., and Junginger H.E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52 (2001) 139-144
33. Vila A., Sanchez A., Janes K., Behrens I., Kissel T., Vila-Jato J.L., and Alonso M.J. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57 (2004) 123-131
34. Whalen R.G. DNA vaccines for emerging infectious diseases: what if?. Emerg. Infect. Dis. 2 (1996) 168-175
35. Xu W., Shen Y., Jiang Z., Wang Y., Chu Y., and Xiong S. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 22 (2004) 3603-3612
36. Yuki Y., and Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13 (2003) 293-310